-
Candida auris Antifungal Pipeline: Review Findings
2026-08-23
This systematic review maps the emerging antifungal pipeline for multidrug-resistant Candida auris by integrating in vitro susceptibility data with efficacy findings from neutropenic animal models. Its main contribution is a comparative framework showing how agents such as manogepix/fosmanogepix, ibrexafungerp, rezafungin, and tetrazoles including Oteseconazole and VT-1598 may expand treatment options while remaining at different stages of validation.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-08-22
MDL 28170 combines nanomolar calpain inhibition with cathepsin B activity and membrane permeability, making it useful for mechanistic neuroprotection research, apoptosis assays, and cell-based injury models. This guide translates recent BDNF/TrkB findings into practical assay design, dosing controls, and troubleshooting strategies.
-
AI-10-49: Mapping RUNX1 Recovery in inv(16) AML
2026-08-22
AI-10-49 is a selective CBFβ-SMMHC inhibitor that enables more than leukemia cell growth studies. This guide presents an assay-centered strategy for connecting fusion-protein disruption with RUNX1 chromatin recovery and the N-MYC/eIF4G1 survival program in inv(16) AML.
-
TET2 Metabolite Binding: A Practical STD NMR Protocol
2026-08-21
This 2025 STAR Protocols paper presents an integrated workflow that combines biochemical TET2 activity assays with saturation transfer difference NMR to distinguish metabolite binding from functional regulation. The protocol validates known TET2 activators and inhibitors and provides a route for identifying additional regulatory metabolites, including glyoxylate.
-
TG003 Cdc2-like Kinase Inhibitor Workflows
2026-08-20
TG003 connects reversible Clk-family inhibition with practical assays for alternative splicing, exon-skipping research, and platinum-resistance biology. This workflow-focused guide covers stock preparation, orthogonal readouts, isoform-aware interpretation, and troubleshooting for more reproducible experiments.
-
c-Myc Peptide for Immunoassay Control
2026-08-20
The c-Myc Peptide provides a sequence-matched way to test antibody specificity, displace tagged fusion proteins, and separate true immunoreactivity from assay background. This workflow also shows how peptide-based controls can strengthen studies of transcription factor stability, including IRF3 regulation by selective autophagy.
-
Leupeptin: Protease Workflow and Troubleshooting
2026-08-19
Leupeptin enables controlled, reversible suppression of serine and cysteine proteases across biochemical, viral, autophagy, and protein degradation workflows. This guide translates a metabolite-binding assay framework into practical inhibitor controls, with fresh-solution handling, orthogonal readouts, and troubleshooting strategies for reproducible results.
-
RepSox: An ALK5 Framework for hiPSC Studies
2026-08-19
RepSox is a potent and selective ALK5 inhibitor for dissecting TGF-β signaling in stem-cell experiments. This article distinguishes mechanistic pathway testing from platelet-production optimization and translates recent hiPSC findings into practical assay decisions.
-
Hexa His Tag Peptide: Clean Elution by Design
2026-08-18
Hexa His tag peptide enables selective, antibody-compatible release of His-tagged proteins from immunoprecipitation workflows. This article explains its competitive mechanism, distinguishes epitope elution from metal-affinity purification, and applies insights from recent CARMIL membrane biology to assay design.
-
GSTM5 Links Genomic Instability to PLK1 Sensitivity
2026-08-18
This study combines multi-omics Mendelian randomization with breast cancer datasets and experimental validation to prioritize GSTM5 as a genomic stability-related gene. The findings connect GSTM5 loss with impaired DNA repair and increased sensitivity to PLK1 inhibition, supporting a biomarker-informed therapeutic hypothesis rather than an established clinical treatment strategy.
-
E-64 for Cathepsin Assays in Lymphoma Research
2026-08-17
E-64 enables mechanistic cysteine protease inhibition while exposing an important assay-design challenge: broad active-site blockade is not the same as selective cathepsin S suppression. This article translates lymphoma antigen-processing research into practical decisions for biochemical, cellular, and immune-function assays.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)
2026-08-17
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit protein degradation during extraction and protease-sensitive assays while avoiding EDTA-mediated divalent-cation chelation. It is suitable for workflows such as Western blotting, co-immunoprecipitation, phosphorylation analysis, and enzyme assays, but not for experiments that specifically require EDTA.
-
Protease Inhibitor Cocktail: Assay Reliability
2026-08-16
This scenario-based guide explains how Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO), SKU K1008, can protect protein endpoints associated with cell viability, proliferation, and cytotoxicity studies. It covers compatibility, dilution, interpretation, and practical criteria for selecting a reliable protein extraction protease inhibitor.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-08-15
This study uses single-cell RNA and B-cell receptor profiling to show how glucose-poor, hypoxic conditions in primary central nervous system lymphoma reshape tumor and microenvironment metabolism. Its central finding is that SLC2A5-mediated fructose uptake represents a functional vulnerability in lymphoma cells and tumor-supportive macrophages, with inhibition suppressing tumor growth in cellular and animal models.
-
Temozolomide Workflows for Glioma DNA-Damage Studies
2026-08-14
Temozolomide (SKU B1399) provides a practical way to model alkylation-driven DNA damage, growth inhibition, and treatment response in glioma and other cancer systems. This guide connects reliable DMSO handling with ATRX-aware combination experiments, dose-response design, and troubleshooting for more interpretable results.